

## **GLEN MILLS, PA -- April 30, 2007**

### **Cost Benefit Study Supports the Use of Longport's Technology in Pressure Ulcer Prevention**

Longport, Inc. (OTC PK: LPTI), a medical technology specialist in high-frequency high resolution ultrasound imaging, today announced interim results from a cost benefit study supporting the use of its EPISCAN I-200 system as an evidence based pressure ulcer prevention tool. Study results showed an expected cost-savings per at-risk resident of \$5,341.00 per year with use of the EPISCAN in concert with current practice standards for pressure ulcer prevention when compared to current pressure ulcer prevention measures alone. Statistical Analysis using Monte Carlo simulation showed the use of the EPISCAN Ultrasound diagnosis to be the preferred option 73.7% of the time and that the decision to use the EPISCAN was very robust and changed only when the incidence of pressure ulceration was below 3.0% in the standard evidence-based group.

The study, which is still on-going, is being undertaken at an extended care rehabilitation nursing home in upstate New York. These interim findings are being presented by Ron Shannon, the principal investigator at the Symposium on Advanced Wound Care (SAWC) and The Wound Healing Society (WHS) meeting in Tampa, Florida (April 28 – May 1, 2007).

Mr. Shannon said, "The timing is right for a cost-effective, diagnostic tool that will give early insight into non-visible pressure ulcer injury so treatment and prevention can begin early. The morbidity associated with the development of pressure ulcers increases patient suffering, nurses' workload and risk of death. Pressure ulcers also increase the length of stay and resultant expense of hospitalization, hardly affordable consequences in today's era of health care economics. We conclude that the EPISCAN, in extended care rehabilitation units, is a cost-benefit to providers for preventing costly pressure ulcers."

Connie Phillips-Jones, RN, MSN, Director of Clinical Support, said, "This is an exciting conclusion and supports the use of the EPISCAN I-200 and will contribute to clinical acceptance based on evidence."

**Further details on this presentation and other clinical study papers can be viewed at the News section of Longport's WEB site.**

**<http://www.longportinc.com/about/news.html>**

**About Longport, Inc.**

Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights and FDA permission to market. The Company's technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at [www.longportinc.com](http://www.longportinc.com).

*Forward-looking Information and the Private Securities Litigation Reform Act of 1995*

*Certain statements in this press release, including statements concerning product development milestones and anticipated events, are "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are*

*difficult to predict. Factors that could affect Longport's actual results include, among others, uncertainties as to the Company's ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport's 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.*